Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70

Mathias Gehrmann1

  • 1University Hospital Regensburg, Dept. Hematology/Oncology, Molecular Oncology, H1 Carreras FoBau Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany. mathias.gehrmann@klinik.uni-regensburg.de

Current Opinion in Investigational Drugs (London, England : 2000)
|June 21, 2006
PubMed

Insights

The apoptosis stimulator STA-4783 enhances tumor cell surface heat shock protein 70 (Hsp70) expression and disrupts cellular structure. Synta Pharmaceuticals is investigating STA-4783 for solid tumor treatment in ongoing clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Solid tumors present significant therapeutic challenges.
  • Targeting tumor cell surface proteins and cytoskeletal integrity is a key strategy in cancer therapy.
  • Heat shock proteins (Hsps) play crucial roles in cellular stress response and survival.

Purpose of the Study:

  • To investigate the mechanism of action of the apoptosis stimulator STA-4783.
  • To evaluate the potential of STA-4783 as a novel therapeutic agent for solid tumors.

Main Methods:

  • STA-4783 treatment of tumor cells.
  • Analysis of heat shock protein 70 (Hsp70) expression on tumor cell surfaces.
  • Assessment of cytoskeletal network integrity.

Main Results:

  • STA-4783 induces expression of Hsp70 on the surface of tumor cells.
  • STA-4783 disrupts the cytoskeletal network within tumor cells.

Conclusions:

  • STA-4783 exhibits a dual mechanism of action involving Hsp70 induction and cytoskeletal disruption.
  • STA-4783 shows promise as a potential treatment for solid tumors, warranting further clinical investigation.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...